InsiderTrades

Form 4 for ZVRA ZEVRA THERAPEUTICS, INC.

Accepted 2025-10-10 00:00:00 ET · period of report 2025-10-10 · accession 0001681098-25-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-10-10 2025-10-10 ZVRA McFarlane Neil F. Pres, CEO, Dir M - OptEx — +50.0K 241.5K +26% —
D 2025-10-10 2025-10-10 ZVRA McFarlane Neil F. Pres, CEO, Dir S - Sale+OE $10.82 -19.5K 222.0K -8% -$211.0K
D 2025-10-10 2025-10-10 ZVRA McFarlane Neil F. Pres, CEO, Dir M - OptEx $0.00 -50.0K 100.0K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-10-10 M A 50,000 — 241,516 D — — (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
2 Common Common Stock 2025-10-10 S D 19,500 $10.82 222,016 D — —
3 Derivative Restricted Stock Unit 2025-10-10 M D 50,000 $0.00 100,000 D $0.00 · — to — 50,000 Common Stock (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. (F3) 25% of the RSUs vested and settled on each of October 10, 2024 and October 10, 2025. The remaining 50% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.